

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

AMICUS THERAPEUTICS US, LLC AND
AMICUS THERAPEUTICS, INC.,

Plaintiffs,

v.

TEVA PHARMACEUTICALS USA, INC.; and
TEVA PHARMACEUTICALS, INC.,

Defendants.

C.A. No. 22-1461-CJB
ANDA CASE

Consolidated

STIPULATION AND [PROPOSED] ORDER TO AMEND SCHEDULING ORDER

WHEREAS the parties have conferred and agreed on reasonable changes to the Scheduling Order (D.I. 137, D.I. 176) to allow discovery and trial to proceed as efficiently as possible;

WHEREAS counsel for each party certifies that they sent a copy of this request to their respective clients in compliance with Local Rule 16.4.

IT IS HEREBY STIPULATED AND AGREED by the parties, subject to the approval of the Court, that the Scheduling Order is amended as follows:

Event	Current Deadline	Parties' Proposed Deadline
Defendants serve final election of asserted prior art	October 4, 2024	November 22, 2024
Completion of fact discovery	October 18, 2024	December 6, 2024
Final deadline to supplement the infringement contentions and invalidity contentions	November 8, 2024	December 20, 2024
Final deadline to supplement noninfringement contentions	November 22, 2024	January 10, 2025

Opening expert reports due	December 19, 2024	January 31, 2025
Rebuttal expert reports due	January 31, 2025	February 28, 2025
Reply expert reports due	March 7, 2025	March 28, 2025
Close of expert discovery	April 10, 2025	April 25, 2025
Deadline to file Daubert motions	April 24, 2025	[No deadline]
Plaintiffs provide draft Joint Proposed Pretrial Order (JPPO)	56 days before submission of Joint Proposed Pretrial Order	56 days before submission of Joint Proposed Pretrial Order May 12, 2025 if the Court sets July 7, 2025 as the Pretrial Conference
Defendants provide response draft JPPO	28 days before submission of Joint Proposed Pretrial Order	28 days before submission of Joint Proposed Pretrial Order June 9, 2025 if the Court sets July 7, 2025 as the Pretrial Conference
Parties submit JPPO	21 days before proposed pretrial conference	21 days before Pretrial Conference June 16, 2025 if the Court sets July 7, 2025 as the Pretrial Conference
Pretrial Conference	June 6, 2026 at 11am	Week of July 7, 2025
5-day Trial begins	June 23, 2026 at 9am	July 21, 2025

Dated: September 26, 2024

BARNES & THORNBURG LLP

/s/ Chad S.C. Stover
Chad S.C. Stover (No. 4919)
222 Delaware Avenue, Suite 1200
Wilmington, DE 19801
Tel: (302) 300-3474
Email: Chad.Stover@btlaw.com

Attorney for Plaintiffs Amicus Therapeutics US, LLC and Amicus Therapeutics, Inc.

SHAW KELLER LLP

/s/ Karen E. Keller
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
I.M. Pei Building
1105 N. Market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
kkeller@shawkeller.com
nhoeschen@shawkeller.com

Attorneys for Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc.

KRATZ & BARRY LLP

/s/ R. Touhey Myer
R. Touhey Myer (No. 5939)
800 N. West Street
Wilmington, DE 19801
(302) 544-9100
tmyer@kratzandbarry.com

Attorney for Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.

IT IS SO ORDERED this _____ day of _____, 2024.

The Honorable Christopher J. Burke
United States Magistrate Judge